Online inquiry

IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12286MR)

This product GTTS-WQ12286MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Renal Cell Carcinoma (RCC), Merkel cell carcinoma (MCC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ12286MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9713MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64407564
GTTS-WQ6498MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CX-072
GTTS-WQ5950MR IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CL-2C
GTTS-WQ15417MR IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA TSR-022
GTTS-WQ5277MR IVTScrip™ mRNA-Anti-IL4-α, CD124(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CD124
GTTS-WQ11015MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MCLA-117
GTTS-WQ15411MR IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA TSR-022
GTTS-WQ10308MR IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LJM716
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW